Tandem Diabetes Care (TNDM) AI Stock Analysis

• Market Cap: $1.41B
• Dividend Yield: N/A
• Average Volume (3M): 2.39M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: 17.87%
• EPS Growth: -57.03%
• Country: US
• Employees: 2,650
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.31
• Shares Outstanding: 67,802,360
• 10 Day Avg. Volume: 2,981,364
• 30 Day Avg. Volume: 2,388,377
• PEG Ratio: 0.43
• Price to Book (P/B): 8.96
• Price to Sales (P/S): 2.51
• P/FCF Ratio: 472.08
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 0.94
• Enterprise Value/Gross Profit: 1.78
• Enterprise Value/Ebitda: -5.29
• 1Y Price Target: $22.71
• Price Target Upside: 3.98% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 17
• EPS Forecast (FY): -2.09
• Revenue Forecast (FY): $997.95M

• Rating: 60 Neutral
• Price Target: $20.50 ▼(-6.14% Downside)

Tandem Diabetes Care's overall stock score reflects a mix of financial challenges and positive market momentum. The earnings call provided a strong positive outlook with record sales and strategic initiatives, which significantly boosted the score. However, financial performance issues, including high leverage and negative profitability, weigh heavily on the overall assessment. The technical analysis indicates bullish momentum, but valuation concerns persist due to the negative P/E ratio.

Positive Factors

Product Innovation

The integration of advanced glucose monitoring technology enhances the product offering, potentially increasing market share and customer retention.

Regulatory Approval

FDA clearance for the Android app expands the user base, improving accessibility and user engagement, which may drive sales growth.

Sales Growth

Record sales indicate strong demand and effective pricing strategies, supporting revenue growth and financial stability.

Negative Factors

High Leverage

Significant leverage increases financial risk and limits flexibility, potentially impacting long-term growth and stability.

Revenue Decline

Decreasing revenue growth suggests challenges in market expansion and competition, which could affect future profitability.

Competitive Pressures

Competitive pressures on new pump starts could hinder market share growth and impact long-term revenue potential.

Tandem Diabetes Care Business Overview & Revenue Model

Company Description

Tandem Diabetes Care, Inc. is a medical device company focused on the design, development, and commercialization of innovative diabetes management products. The company specializes in insulin delivery systems, including its flagship product, the t:slim X2 insulin pump, which features advanced technology such as continuous glucose monitoring integration and customizable settings to enhance the user experience. Tandem serves individuals with diabetes, healthcare providers, and payers, aiming to improve the quality of life for those managing this chronic condition.

How the Company Makes Money

Tandem Diabetes Care generates revenue primarily through the sale of its insulin delivery devices, including the t:slim X2 insulin pump and associated supplies such as infusion sets and cartridges. The company operates on a direct sales model, selling products to healthcare providers, diabetes clinics, and directly to consumers. Additionally, Tandem benefits from partnerships with insulin manufacturers and healthcare systems that facilitate the integration of its products with other diabetes management solutions. Revenue is also supported by reimbursement from insurance companies, which cover a portion of the costs for patients using Tandem's devices. Furthermore, the company's ongoing innovation and product development efforts allow it to maintain a competitive edge, potentially leading to increased sales and market share.

Tandem Diabetes Care Financial Statement Overview

Summary

Tandem Diabetes Care is facing significant financial challenges, with declining revenue growth and profitability issues. The high leverage and negative return on equity indicate financial risk, while the cash flow position shows some improvement. The company needs to focus on revenue growth, cost management, and debt reduction to enhance its financial performance and stability.

Income Statement

Tandem Diabetes Care has experienced a decline in revenue growth, with a negative growth rate of -10.17% in the TTM period. The company is facing profitability challenges, as indicated by negative net profit and EBIT margins. However, the gross profit margin remains relatively stable at 53.23%, suggesting some operational efficiency. The company needs to address its declining revenue and improve its cost management to enhance profitability.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 3.38 in the TTM period, indicating significant leverage and potential financial risk. The return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is low, suggesting limited financial stability. Tandem Diabetes Care should focus on reducing its debt levels and improving its equity position to strengthen its financial health.

Cash Flow

The cash flow statement shows a positive free cash flow growth rate of 32.07% in the TTM period, indicating improved cash generation. However, the operating cash flow to net income ratio is negative, highlighting challenges in converting income into cash. The free cash flow to net income ratio is high, suggesting that the company is generating cash despite net losses. Tandem Diabetes Care should focus on enhancing its operational cash flow to support its financial stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.01B	940.20M	747.72M	801.22M	702.80M	498.83M
Gross Profit	536.01M	489.57M	367.69M	412.99M	376.21M	260.52M
EBITDA	-179.70M	-99.13M	-196.46M	-74.21M	34.06M	-13.03M
Net Income	-203.37M	-96.03M	-222.61M	-94.59M	15.57M	-34.38M
Balance Sheet
Total Assets	874.65M	967.66M	952.66M	1.05B	905.14M	716.41M
Cash, Cash Equivalents and Short-Term Investments	319.11M	438.33M	467.91M	616.90M	623.81M	484.94M
Total Debt	449.28M	473.56M	415.67M	419.88M	314.67M	228.32M
Total Liabilities	741.69M	704.56M	639.03M	612.84M	472.02M	350.11M
Stockholders Equity	132.97M	263.10M	313.63M	439.95M	433.11M	366.31M
Cash Flow
Free Cash Flow	-25.13M	4.99M	-58.61M	16.37M	87.85M	-7.63M
Operating Cash Flow	-8.79M	24.23M	-31.81M	50.46M	111.36M	24.67M
Investing Cash Flow	92.86M	-23.48M	-85.74M	33.17M	-186.88M	-296.06M
Financing Cash Flow	-43.67M	8.37M	4.11M	16.88M	51.93M	314.44M

Tandem Diabetes Care Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNDM, the sentiment is Positive. The current price of 21.84 is above the 20-day moving average (MA) of 17.28, above the 50-day MA of 15.25, and above the 200-day MA of 17.72, indicating a bullish trend. The MACD of 1.73 indicates Negative momentum. The RSI at 77.19 is Negative, neither overbought nor oversold. The STOCH value of 94.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TNDM.

Tandem Diabetes Care Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EW	79 Outperform	$50.38B	36.96	13.59%	―	0.19%	65.58%
PODD	74 Outperform	$23.13B	95.42	19.68%	―	27.12%	-41.72%
MDT	74 Outperform	$135.13B	28.44	9.81%	2.69%	5.34%	13.15%
DXCM	69 Neutral	$24.06B	34.34	30.63%	―	14.21%	5.66%
TNDM	60 Neutral	$1.41B	―	-109.73%	―	17.87%	-57.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHG	50 Neutral	$26.44B	―	―	3.18%	-0.76%	-55.03%

Tandem Diabetes Care Corporate Events

Tandem Diabetes Care Appoints Sandra Beaver to Board

On November 7, 2025, Tandem Diabetes Care appointed Sandra Beaver to its Board of Directors, expanding the board from eight to nine members. Ms. Beaver, a seasoned finance executive with over 20 years of experience, will serve on the Audit Committee and the Cybersecurity and Data Privacy Committee. Her appointment is expected to support Tandem’s growth strategy as it continues to innovate in digital health solutions and expand into new markets.

The most recent analyst rating on (TNDM) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.

Tandem Diabetes Care Q3 2025 Earnings: Record Sales & Growth

Tandem Diabetes Care’s recent earnings call for the third quarter of 2025 painted a largely positive picture, highlighting significant achievements such as record sales and improved margins. These successes were attributed to strategic initiatives in pricing, product innovation, and pharmacy expansion. Despite facing challenges like competitive pressures on new pump starts and transition-related impacts in Europe, the overall sentiment was optimistic, with the highlights significantly outweighing the lowlights.

Tandem Diabetes Care Reports Record Third-Quarter Sales

Tandem Diabetes Care, Inc. is a global company specializing in the development and sale of advanced insulin delivery systems, primarily serving the diabetes technology sector. The company is known for its innovative products like the Tandem Mobi and t:slim X2 insulin pumps, which incorporate advanced hybrid closed-loop technology.

Tandem Diabetes Care’s New Study: A Game Changer for Type 1 Diabetes Management?

Study Overview: Tandem Diabetes Care is conducting a study titled ‘The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France.’ The study aims to evaluate the safety, performance, and quality of life improvements associated with the Control-IQ system in individuals with Type 1 Diabetes. This research is significant as it assesses real-world applications of the system over a 12-month period, providing valuable insights into its effectiveness and user experience.